SCHEMBL915272

SCHEMBL915272

CC(C)C(OC(=O)ON1C(=O)CCC1=O)OC(=O)C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634453 0.85 MGLL (0.32) MGLL
SCHEMBL917047 0.85 MGLL (0.32) MGLL
SCHEMBL916283 0.83 MGLL (0.33) MGLL
SCHEMBL915140 0.82 MGLL (0.32) MGLL
SCHEMBL14689006 0.82 MGLL (0.32) MGLL
SCHEMBL4309617 0.82 MGLL (0.32) MGLL
SCHEMBL916334 0.81 MGLL (0.32) MGLL
SCHEMBL15991954 0.79 MGLL (0.31) MGLL
SCHEMBL15992178 0.79 PSMB8 (0.32) MGLL
SCHEMBL2974670 0.79 MMP1 (0.39) MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112920092-B Prodrugs of glutamine analogues 约翰霍普金斯大学 2024-04-26 CN disclosed
US-11926640-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2024-03-12 US disclosed
EP-3328827-B1 PRODRUGS OF GLUTAMINE ANALOGS UNIV JOHNS HOPKINS (US) 2023-07-05 EP disclosed
EP-3328827-B1 PRODRUGS OF GLUTAMINE ANALOGS UNIV JOHNS HOPKINS (US) 2023-07-05 EP disclosed
US-11434198-B2 Compounds and methods for the treatment of neurodegenerative diseases Resilio Therapeutics, LLC (US) 2022-09-06 US disclosed
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) 2021-07-08 US disclosed
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) 2021-07-08 US disclosed
US-20210206713-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Resilio Therapeutics, LLC 2021-07-08 US disclosed
CN-112920092-A Prodrugs of glutamine analogs 约翰霍普金斯大学 2021-06-08 CN disclosed
US-10954257-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2021-03-23 US disclosed
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS XENOPORT, INC. 2009-09-17 US disclosed
US-7572830-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2009-08-11 US disclosed
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-06-26 US disclosed
EP-1919859-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE Xenoport, Inc. (US) 2008-05-14 EP disclosed
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-04-24 US disclosed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US disclosed
US-7300956-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-11-27 US disclosed
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-03-08 US disclosed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US disclosed
WO-2007002013-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206713-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OTC, OAT, ODC1 MGLL 2515/4885
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, ABAT, SI MGLL 420/4885
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 MGLL 2012/4885
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI MGLL 420/4885
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS APEH, ABAT, GABARAPL1 MGLL 393/4885
US-11926640-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 MGLL 1686/4885
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use ACMSD, APEH, CPS1 MGLL 906/4885
US-10954257-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 MGLL 1686/4885
US-11434198-B2 Compounds and methods for the treatment of neurodegenerative diseases OTC, OAT, ODC1 MGLL 2515/4885
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 MGLL 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.